Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA

Context: Sickle cell disease is a common inherited blood disorder affecting millions of people worldwide. Due to lack of progress in drug discovery for a suitable treatment, sufferers often turn to traditional medicines that take advantage of the plant extracts activity used by traditional healers....

Full description

Bibliographic Details
Main Authors: Joran Villaret, Guillaume Marti, Frédérique Dubois, Karine Reybier, Noémie Gaudre, Mohamed Haddad, Alexis Valentin
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Pharmaceutical Biology
Subjects:
Online Access:http://dx.doi.org/10.1080/13880209.2018.1501585
id doaj-2a214f8c045148babc0855444dfc2d11
record_format Article
spelling doaj-2a214f8c045148babc0855444dfc2d112020-11-25T01:22:14ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162018-01-0156138539210.1080/13880209.2018.15015851501585Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACAJoran Villaret0Guillaume Marti1Frédérique Dubois2Karine Reybier3Noémie Gaudre4Mohamed Haddad5Alexis Valentin6Université de Toulouse, IRD, UPSUniversité de Toulouse, IRD, UPSInstitut Universitaire du Cancer de Toulouse – OncopoleUniversité de Toulouse, IRD, UPSPôle Cardiovasculaire et Métabolique, Hôpital RangueilUniversité de Toulouse, IRD, UPSUniversité de Toulouse, IRD, UPSContext: Sickle cell disease is a common inherited blood disorder affecting millions of people worldwide. Due to lack of progress in drug discovery for a suitable treatment, sufferers often turn to traditional medicines that take advantage of the plant extracts activity used by traditional healers. Objective: This study optimizes an anti-sickling screening test to identify preparations capable of reverting sickle cells back to the morphology of normal red blood cells. We focused on the miniaturization and practicability of the assay, so that it can be adapted to the laboratory conditions commonly found in less developed countries. Materials and methods: We tested two traditional anti-sickling herbal medicines, FACA® and DREPANOSTAT®, composed of Zanthoxylum zanthoxyloides (Lam.) Zepern. & Timler (Rutaceae) and Calotropis procera (Aiton) Dryand. (Apocynaceae) at screening concentrations of hydroethanol extracts from 0.2 to 1 mg/mL. Potential bioactive molecules present in the extracts were profiled using Ultra High Performance Liquid Chromatography coupled with High Resolution Mass Spectrometry (UHPLC-HRMS/MS) method, identified through HRMS, MS/MS spectra and in silico fragmentation tools. Results: Hydroethanol extracts of FACA® and DREPANOSTAT® showed low anti-sickling activity, inhibiting less than 10% of the sickling process. The UHPLC-HRMS/MS profiles identified 28 compounds (18 in FACA® and 15 in DREPANOSTAT®, including common compounds) among which l-phenylalanine is already described as potential anti-sickling agent. When used as positive control, 7 mg/mL phenylalanine reduced the sickled RBC to 52%. Discussion and conclusions: This assay has been optimized for the easy screening of plant extracts or extracted compounds from bioassay guided fractionation, valuable to laboratories from less developed countries.http://dx.doi.org/10.1080/13880209.2018.1501585sickle cell anemiametabolomicsuhplc-hrmstraditional medicineszanthoxylum zanthoxiloidescalotropis procera
collection DOAJ
language English
format Article
sources DOAJ
author Joran Villaret
Guillaume Marti
Frédérique Dubois
Karine Reybier
Noémie Gaudre
Mohamed Haddad
Alexis Valentin
spellingShingle Joran Villaret
Guillaume Marti
Frédérique Dubois
Karine Reybier
Noémie Gaudre
Mohamed Haddad
Alexis Valentin
Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
Pharmaceutical Biology
sickle cell anemia
metabolomics
uhplc-hrms
traditional medicines
zanthoxylum zanthoxiloides
calotropis procera
author_facet Joran Villaret
Guillaume Marti
Frédérique Dubois
Karine Reybier
Noémie Gaudre
Mohamed Haddad
Alexis Valentin
author_sort Joran Villaret
title Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
title_short Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
title_full Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
title_fullStr Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
title_full_unstemmed Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA
title_sort adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to drepanostat and faca
publisher Taylor & Francis Group
series Pharmaceutical Biology
issn 1388-0209
1744-5116
publishDate 2018-01-01
description Context: Sickle cell disease is a common inherited blood disorder affecting millions of people worldwide. Due to lack of progress in drug discovery for a suitable treatment, sufferers often turn to traditional medicines that take advantage of the plant extracts activity used by traditional healers. Objective: This study optimizes an anti-sickling screening test to identify preparations capable of reverting sickle cells back to the morphology of normal red blood cells. We focused on the miniaturization and practicability of the assay, so that it can be adapted to the laboratory conditions commonly found in less developed countries. Materials and methods: We tested two traditional anti-sickling herbal medicines, FACA® and DREPANOSTAT®, composed of Zanthoxylum zanthoxyloides (Lam.) Zepern. & Timler (Rutaceae) and Calotropis procera (Aiton) Dryand. (Apocynaceae) at screening concentrations of hydroethanol extracts from 0.2 to 1 mg/mL. Potential bioactive molecules present in the extracts were profiled using Ultra High Performance Liquid Chromatography coupled with High Resolution Mass Spectrometry (UHPLC-HRMS/MS) method, identified through HRMS, MS/MS spectra and in silico fragmentation tools. Results: Hydroethanol extracts of FACA® and DREPANOSTAT® showed low anti-sickling activity, inhibiting less than 10% of the sickling process. The UHPLC-HRMS/MS profiles identified 28 compounds (18 in FACA® and 15 in DREPANOSTAT®, including common compounds) among which l-phenylalanine is already described as potential anti-sickling agent. When used as positive control, 7 mg/mL phenylalanine reduced the sickled RBC to 52%. Discussion and conclusions: This assay has been optimized for the easy screening of plant extracts or extracted compounds from bioassay guided fractionation, valuable to laboratories from less developed countries.
topic sickle cell anemia
metabolomics
uhplc-hrms
traditional medicines
zanthoxylum zanthoxiloides
calotropis procera
url http://dx.doi.org/10.1080/13880209.2018.1501585
work_keys_str_mv AT joranvillaret adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT guillaumemarti adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT frederiquedubois adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT karinereybier adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT noemiegaudre adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT mohamedhaddad adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
AT alexisvalentin adaptationofamicrobeadassayfortheeasyevaluationoftraditionalantisicklingmedicinesapplicationtodrepanostatandfaca
_version_ 1725126967761567744